[1]
|
Centanni, M., Benvenga, S. and Sachmechi, I. (2017) Diagnosis and Management of Treatment-Refractory Hypothyroidism: An Expert Consensus Report. Journal of Endocrinological Investigation, 40, 1289-1301. https://doi.org/10.1007/s40618-017-0706-y
|
[2]
|
Wyse, E.P., McConahey, W.M., Woolner, L.B., et al. (1968) Ophthalmopathy without Hyperthyroidism in Patients with Histologic Hashimoto’s Thyroiditis. The Journal of Clinical Endocrinology & Metabolism, 28, 1623-1629. https://doi.org/10.1210/jcem-28-11-1623
|
[3]
|
Kashkouli, M.B., Pakdel, F., Kiavash, V., et al. (2011) Hyperthyroid vs Hypothyroid Eye Disease: The Same Severity and Activity. Eye, 25, 1442-1446. https://doi.org/10.1038/eye.2011.186
|
[4]
|
Bartalena, L., Baldeschi, L., Boboridis, K., et al. (2016) The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. European Thyroid Journal, 5, 9-26. https://doi.org/10.1159/000443828
|
[5]
|
Bahn, R.S., Burch, H.B., Cooper, D.S., et al. (2011) Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocrine Practice, 17, 456-520. https://doi.org/10.4158/EP.17.3.456
|
[6]
|
Mourits, M.P., Koornneef, L., Wiersinga, W.M., et al. (1989) Clinical Criteria for the Assessment of Disease Activity in Graves’ Ophthalmopathy: A Novel Approach. British Journal of Ophthalmology, 73, 639-644. https://doi.org/10.1136/bjo.73.8.639
|
[7]
|
Ernst, F.R., Barr, P., Elmor, R., et al. (2017) The Economic Impact of Levothyroxine Dose Adjustments: The CONTROL HE Study. Clinical Drug Investigation, 37, 71-83. https://doi.org/10.1007/s40261-016-0462-3
|
[8]
|
Wiersinga, W.M. (2019) Graves’ Disease: Can It Be Cured? Endocrinology and Metabolism, 34, 29-38. https://doi.org/10.3803/EnM.2019.34.1.29
|
[9]
|
Virili, C., Antonelli, A., Santaguida, M.G., et al. (2019) Gastrointestinal Malabsorption of Thyroxine. Endocrine Reviews, 40, 118-136. https://doi.org/10.1210/er.2018-00168
|
[10]
|
Wiesner, A., Gajewska, D. and Pasko, P. (2021) Levothyroxine Interactions with Food and Dietary Supplements—A Systematic Review. Pharmaceuticals, 14, Article 206. https://doi.org/10.3390/ph14030206
|
[11]
|
Huang, L.L., Deng, J.H., Xie, J.X., et al. (2021) Integrin-Linked Kinase (ILK) Regulates Urinary Stem Cells Differentiation into Smooth Muscle via NF-κB Signal Pathway. Stem Cells International, 2021, Article ID: 6633111. https://doi.org/10.1155/2021/6633111
|
[12]
|
中华医学会内分泌学分会. 成人甲状腺功能减退症诊治指南[J]. 中华内分泌代谢杂志, 2017, 33(2), 167-180.
|
[13]
|
Flynn, R.W., Bonellie, S.R., Jung, R.T., et al. (2010) Serum Thyroid-Stimulating Hormone Concentration and Morbidity From Cardiovascular Disease and Fractures in Patients on Long-Term Thyroxine Therapy. The Journal of Clinical Endocrinology & Metabolism, 95, 186-193. https://doi.org/10.1210/jc.2009-1625
|
[14]
|
Virili, C., Trimboli, P., Romanelli, F., et al. (2016) Liquid and Softgel Levothyroxine Use in Clinical Practice: State of the Art. Endocrine, 54, 3-14. https://doi.org/10.1007/s12020-016-1035-1
|
[15]
|
Smith, T.J. and Hegedus, L. (2016) Graves’ Disease. The New England Journal of Medicine, 375, 1552-1565. https://doi.org/10.1056/NEJMra1510030
|
[16]
|
Kahaly, G.J., Bartalena, L., Hegedus, L., et al. (2018) 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. European Thyroid Journal, 7, 167-186. https://doi.org/10.1159/000490384
|
[17]
|
Fox, T.J. and Anastasopoulou, C. (2021) Graves Orbitopathy. Stat Pearls, Treasure Island.
|
[18]
|
Valyasevi, R.W., Erickson, D.Z., Harteneck, D.A., et al. (1999) Differentiation of Human Orbital Preadipocyte Fibroblasts Induces Expression of Functional Thyrotropin Receptor. The Journal of Clinical Endocrinology and Metabolism, 84, 2557-2562. https://doi.org/10.1210/jc.84.7.2557
|
[19]
|
Barrio, J., Sabater, A.L., Bonet-Farriol, E., et al. (2015) Graves’ Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management. Journal of Ophthalmology, 2015, Article ID: 249125. https://doi.org/10.1155/2015/249125
|
[20]
|
Khong, J.J., Finch, S., De Silva, C., et al. (2016) Risk Factors for Graves’ Orbitopathy: The Australian Thyroid-Associated Orbitopathy Research (ATOR) Study. The Journal of Clinical Endocrinology & Metabolism, 101, 2711-2720. https://doi.org/10.1210/jc.2015-4294
|
[21]
|
Drui, D., Du Pasquier Fediaevski, L., Vignal Clermont, C., et al. (2018) Graves’ Orbitopathy: Diagnosis and Treatment. Annales d’Endocrinologie, 79, 656-664. https://doi.org/10.1016/j.ando.2018.08.005
|
[22]
|
闫春芳, 张朝霞, 罗燕, 等. ABO血型与甲状腺相关眼病的相关性研究[J]. 中华眼外伤职业眼病杂志, 2023, 45(6): 440-444.
|
[23]
|
中国医学会眼科学分会眼整形眼眶病学组, 中华医学会内分泌学分会甲状腺学组. 中国甲状腺相关眼病诊断和治疗指南(2022)年[J]. 中华眼科杂志, 2022, 58(9): 646-668.
|
[24]
|
Marcocci, C., Kahaly, G.J., Krassas, G.E., et al. (2011) Selenium and the Course of Mild Graves’ Orbitopathy. The New England Journal of Medicine, 364, 1920-1931. https://doi.org/10.1056/NEJMoa1012985
|
[25]
|
Smith, T.J., Kahaly, G.J., Ezra, D.G., et al. (2017) Teprotumumab for Thyroid-Associated Ophthalmopathy. The New England Journal of Medicine, 376, 1748-1761. https://doi.org/10.1056/NEJMoa1614949
|
[26]
|
Bartalena, L. and Fatourechi, V. (2014) Extrathyroidal Manifestations of Graves’ Disease: A 2014 Update. Journal of Endocrinological Investigation, 37, 691-700. https://doi.org/10.1007/s40618-014-0097-2
|
[27]
|
Fatourechi, V., Ahmed, D.D. and Schwartz, K.M. (2002) Thyroid Acropachy: Report of 40 Patients Treated at a Single Institution in a 26-Year Period. The Journal of Clinical Endocrinology & Metabolism, 87, 5435-5441. https://doi.org/10.1210/jc.2002-020746
|
[28]
|
Schwartz, K.M., Fatourechi, V., Ahmed, D.D., et al. (2002) Dermopathy of Graves’ Disease (Pretibial Myxedema): Long-Term Outcome. The Journal of Clinical Endocrinology & Metabolism, 87,438-446. https://doi.org/10.1210/jcem.87.2.8220
|
[29]
|
Takasu, N., Higa, H. and Kinjou, Y. (2010) Treatment of Pretibial Myxedema (PTM) with Topical Steroid Ointment Application with Sealing Cover (Steroid Occlusive Dressing Technique: Steroid ODT) in Graves’ Patients. Internal Medicine, 49, 665-669. https://doi.org/10.2169/internalmedicine.49.2617
|
[30]
|
Susser, W.S., Heermans, A.G., Chapman, M.S., et al. (2002) Elephantiasic Pretibial Myxedema: A Novel Treatment for an Uncommon Disorder. Journal of the American Academy of Dermatology, 46,723-726. https://doi.org/10.1067/mjd.2002.119655
|
[31]
|
Vannucchi, G., Campi, I., Covelli, D., et al. (2013) Treatment of Pretibial Myxedema with Dexamethazone Injected Subcutaneously by Mesotherapy Needles. Thyroid, 23, 626-632. https://doi.org/10.1089/thy.2012.0429
|